Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
Erik Olsson(Uppsala University), Antonios Valachis(Örebro University Hospital), Henrik Lindman(Uppsala University), Ute Krüger(Landstinget i Kalmar län), Anna-Karin Wennstig(Sundsvall Municipality), Haidar Mir Ali(Landstinget i Kalmar län), Viktoria Thurfjell(Uppsala University Hospital), Marie Sundqvist(Landstinget i Kalmar län), Evangelos Digkas(Uppsala University)
Cited by 1
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260